The Global Initiative for Asthma (GINA) 2019 report makes a major change in asthma management by recommending that adults and adolescents with mild symptomatic asthma (Step 1) receive as-needed low-dose inhaled corticosteroid (ICS)–formoterol rather than a short-acting β2-agonist alone [1]. At step 2, daily low-dose ICS is recommended, and GINA 2019 considers low-dose ICS–formoterol reliever as an alternative “preferred controller”. The GINA recommendation to use as-required ICS-formoterol in symptomatic mild asthma is applicable to smokers with a low cumulative smoking history, but evidence is lacking for its effectiveness in smokers with medium and high tobacco use http://bit.ly/2Xqqluu

中文翻译：

---

GINA 对有症状的轻度哮喘和吸烟史成人的建议

全球哮喘防治倡议 (GINA) 2019 年报告通过建议患有轻度症状性哮喘（步骤 1）的成人和青少年根据需要接受低剂量吸入性皮质类固醇 (ICS)-福莫特罗，而不是短时-福莫特罗，从而对哮喘管理做出重大改变。单独作用 β2-激动剂 [1]。在第 2 步，建议每日使用低剂量 ICS，GINA 2019 将低剂量 ICS-福莫特罗缓解剂视为替代的“首选控制器”。GINA 建议在有症状的轻度哮喘中按需使用 ICS-福莫特罗适用于累积吸烟史较低的吸烟者，但缺乏证据表明其对中度和高度使用烟草的吸烟者的有效性 http://bit.ly/2Xqqluu